CHANDLER DENSON: Open Payments
NPI 1609521418 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$716 in 29 payments from 9 companies in 2025. Trend: 2023 $1,496 · 2024 $461 · 2025 $716
Food & beverage: $716
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $181 |
| Neurocrine BioSciences, Inc. | 6 | $150 |
| Alkermes, Inc. | 6 | $139 |
| E.R. Squibb & Sons, L.L.C. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $57 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $17 |
Products named: AUSTEDO XR, INGREZZA, ARISTADA, COBENFY, CAPLYTA, FANAPT, REXULTI, Sunosi.
Industry payments across AL — which companies pay providers there.
